Loading…
Ishita Drugs & Industries (BSE 524400)₹74.90+5.49%Pharmaceuticals
Ishita Drugs & Industries is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 28.3 against a peer median of 15.6, and ROCE of 8.6% against a peer median of 4.0%, and latest-quarter sales growth of −32.8% against a peer median of 3.7%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Goldline Pharmaceutical | 29 | 5.0 | 30.6 | 39.4 | 0.88 | 0.0 | 31 | 4 | — | — | vs BSE 524400 |
| Medi Caps | 26 | — | −9.3 | −9.2 | 0.00 | 0.0 | 12 | −3 | 3.7 | — | vs BSE 524400 |
| Bacil Pharma | 24 | 15.6 | — | — | 0.00 | 0.0 | 0 | 2 | — | — | vs BSE 524400 |
| Lasa Supergenerics | 24 | — | −18.0 | −19.6 | 0.20 | 0.0 | 25 | −34 | −100.3 | — | vs BSE 524400 |
| Welcure Drugs & Pharmaceuticals | 24 | — | −3.0 | −5.5 | 0.00 | 0.0 | 366 | −5 | −100.0 | −1,768.9 | vs BSE 524400 |
| Walpar Nutritions | 24 | 9.5 | 14.9 | 13.9 | 0.89 | 0.0 | 79 | 3 | 7.8 | 6.4 | vs BSE 524400 |
| Ishita Drugs & Industries | 22 | 28.3 | 8.6 | 7.0 | 0.01 | 0.0 | 15 | 1 | −32.8 | −36.7 | — |
| Venmax Drugs & Pharmaceuticals | 21 | 54.3 | 3.0 | 2.7 | 0.02 | 0.0 | 8 | 0 | 1,128.1 | −87.0 | vs BSE 524400 |
| Span Divergent | 20 | — | −30.0 | −41.5 | 0.48 | 0.0 | 17 | −3 | −4.6 | — | vs BSE 524400 |
| Mono Pharmacare | 18 | 52.6 | 5.0 | 1.1 | 1.78 | 0.0 | 166 | 0 | 22.1 | −100.0 | vs BSE 524400 |
| Centuple Global | 18 | 11.6 | 15.0 | 12.7 | 0.29 | 0.0 | 575 | 2 | 1,07,642.3 | −1,040.0 | vs BSE 524400 |
| Peer median | 24 | 15.6 | 4.0 | 1.9 | 0.20 | 0.0 | 25 | 0 | 3.7 | −93.5 |
Listed companies closest to Ishita Drugs & Industries in Pharmaceuticals include Goldline Pharmaceutical, Medi Caps, Bacil Pharma, Lasa Supergenerics, Welcure Drugs & Pharmaceuticals, Walpar Nutritions, Venmax Drugs & Pharmaceuticals, Span Divergent.
Goldline Pharmaceutical, with a market cap of ₹28.55 Cr.
Ishita Drugs & Industries trades at a P/E of 28.3; the median of its peer set is 15.6. A P/E above or below the median is a description, not a judgement on value.
Ishita Drugs & Industries' return on capital employed is 8.6%, above the peer median of 4.0%.